Synonyms: compound 38 [PMID: 16640337] | GW427353
Compound class:
Synthetic organic
Comment: Solabegron (GW427353) is a highly potent and selective β3-adrenoceptor agonist [5]. β3 agonists (e.g. mirabegron and solabegron) failed to show efficacy for their original clinical indication, obesity/type 2 diabetes, but have been repurposed/repositioned for the treatment of the overactive bladder syndrome [3].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
References |
1. Biers SM, Reynard JM, Brading AF. (2006)
The effects of a new selective beta3-adrenoceptor agonist (GW427353) on spontaneous activity and detrusor relaxation in human bladder. BJU Int, 98 (6): 1310-4. [PMID:17026593] |
2. Igawa Y, Michel MC. (2013)
Pharmacological profile of β3-adrenoceptor agonists in clinical development for the treatment of overactive bladder syndrome. Naunyn Schmiedebergs Arch Pharmacol, 386 (3): 177-83. [PMID:23263450] |
3. Michel MC, Korstanje C. (2016)
β3-Adrenoceptor agonists for overactive bladder syndrome: Role of translational pharmacology in a repositioning clinical drug development project. Pharmacol Ther, 159: 66-82. [PMID:26808167] |
4. Schemann M, Hafsi N, Michel K, Kober OI, Wollmann J, Li Q, Zeller F, Langer R, Lee K, Cellek S. (2010)
The beta3-adrenoceptor agonist GW427353 (Solabegron) decreases excitability of human enteric neurons via release of somatostatin. Gastroenterology, 138 (1): 266-74. [PMID:19786030] |
5. Uehling DE, Shearer BG, Donaldson KH, Chao EY, Deaton DN, Adkison KK, Brown KK, Cariello NF, Faison WL, Lancaster ME et al.. (2006)
Biarylaniline phenethanolamines as potent and selective beta3 adrenergic receptor agonists. J Med Chem, 49 (9): 2758-71. [PMID:16640337] |